Startups
Revolutionizing RNAi therapies for metabolic and autoimmune diseases through its Ligand and Enhancer Assisted (LEAD™) Technology.
Overview
Location
China
Employees
51-200
Total raised
$110M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 17, 2025 | SymBiosis | symbiosis.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 19, 2025 | Sanegene Bio Closes Over $110 Million Series B | WOBURN, MA, Sanegene Bio has raised more than $110 million in a series B round. >> Click here for more funding data on Sanegene Bio >> To export Sanegene Bio funding data to PDF and Excel, click here According to 'The Phar... |
| Dec 9, 2025 | Tencent-backed SanegeneBio secures over $110m Series B | |
| Nov 8, 2025 | SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly | -Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research a... |
| Dec 4, 2023 | Deals in brief: Igloo and Gravel secure funding, COP28 participants step up financial commitments, multiple China, India, and Middle East deals, and more | Igloo raises USD 36 million in pre-Series C funding The insurtech company has announced the completion of its pre-Series C funding round, raising USD 36 million. The round was led by Eurazeo, utilizing its BNP Paribas Cardif-backed insurtec... |
| Under pressure, biotech and pharma grapple with how to take climate action | As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make en... | |
| Sanegene Bio | “SanegeneBio is an emerging RNAi-based company developing innovative RNA interference (RNAi) therapeutics driven by the cutting-edge delivery technology. Founded in 2021, SanegeneBio was propelled by a team of industry-leading experts and h... |
Reviews 0
FAQ about SanegeneBio
How much funding has SanegeneBio raised?
SanegeneBio has raised $110M in total across 1 funding round.
Who has invested in SanegeneBio?
Parsers VC lists 2 investors of SanegeneBio, among them SymBiosis.
What has the press written about SanegeneBio?
Parsers VC has collected 7 articles mentioning SanegeneBio, among them “Sanegene Bio Closes Over $110 Million Series B” (Dec 19, 2025) and “Tencent-backed SanegeneBio secures over $110m Series B” (Dec 9, 2025).
Is SanegeneBio still active?
Yes, SanegeneBio is active; its latest activity on Parsers VC dates from Jul 10, 2026.